Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 versus semaglutide in early type 2 diabetes mellitus with obesity
CTR20234187Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide, semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Innovent Biologics. Started Feb 2024; status: completed.
02
Drugs
mazdutidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on CTR20234187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234187.